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Abstract 
 
Background: To compare PREDICT and CancerMath, two widely used prognostic models for 
invasive breast cancer, taking into account their clinical utility. Furthermore, it is unclear whether 
these models could be improved. 
 
Methods: A dataset of 5729 women was used for model development. A Bayesian variable 
selection algorithm was implemented to stochastically search for important interaction terms 
among the predictors. The derived models were then compared in three independent datasets (n 
= 5534). We examined calibration, discrimination and performed decision curve analysis. 
 
Results: CancerMath demonstrated worse calibration performance compared to PREDICT in 
oestrogen receptor (ER)-positive and ER-negative tumours. The decline in discrimination 
performance was -4.27% (-6.39 – -2.03) and -3.21% (-5.9 – -0.48) for ER-positive and ER-negative 
tumours, respectively. Our new models matched the performance of PREDICT in terms of 
calibration and discrimination, but offered no improvement. Decision curve analysis showed 
predictions for all models were clinically useful for treatment decisions made at risk thresholds 
between 5% and 55% for ER-positive tumours and at thresholds of 15% to 60% for ER-negative 
tumours. Within these threshold ranges, CancerMath provided the lowest clinical utility amongst 
all the models.  
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Conclusions: Survival probabilities from PREDICT offer both improved accuracy and discrimination 
over CancerMath. Using PREDICT to make treatment decisions offers greater clinical utility than 
CancerMath over a range of risk thresholds. Our new models performed as well as PREDICT, but 
no better, suggesting that, in this setting, including further interaction terms offers no predictive 
benefit. 
 
 
 
Keywords: Bayesian variable selection; breast cancer; CancerMath; decision curve analysis; 
external validation; prediction model; PREDICT. 
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Introduction 
Accurate prognostic predictions are crucial in clinical decision making around adjuvant therapy 
following surgery for early breast cancer. Adjuvant therapies, such as chemotherapy, are 
associated with serious side-effects and so are typically only in the patient's interest when there is 
non-negligible risk of mortality. Inaccurate risk predictions can lead to over-prescription of 
chemotherapy to patients who do not require it, and unnecessarily increased mortality among 
patients whose risk is underestimated. Over the years, several predictive models have been 
proposed, that can aid in the decision to treat patients with systemic therapy, based on clinical 
and pathological factors (1).  
 One such tool, PREDICT, was proposed in 2010 (www.predict.nhs.uk). It provides 
predictions of 5- and 10-year breast cancer survival and the benefits of hormonal therapy, 
chemotherapy and trastuzumab (2). The model utilizes data on factors such as patient age, 
tumour size, tumour grade, number of positive nodes, oestrogen receptor (ER) status, Ki67 status, 
mode of detection and human epidermal growth factor receptor 2 (HER2) status (3). PREDICT has 
been validated in many cohorts (4–6). An updated version improving performance has been 
published recently (7). Another prognostic tool, CancerMath, was proposed in 2009 
(http://cancer.lifemath.net/). CancerMath models risk predictions as a function of tumour size, 
number of nodes and various other prognostic factors (8), and is also able to predict the impact of 
various adjuvant therapies. CancerMath has been validated using data from patients in the United 
States (9), as well as a South East population (10). 
 Although both PREDICT and CancerMath are widely used for cancer prognosis, to date, 
there is limited data on the concordance of these two prediction models. Only, Laas et al., (11) 
compared the overall performance of CancerMath and PREDICT using information from 965 
women with ER-positive and HER2-negative early breast cancer from the United States and 
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Canada. Further comparison in larger populations may be necessary. Furthermore, risk models are 
routinely evaluated using only standard performance metrics of discrimination and calibration. 
Such metrics give limited information as to the clinical value of a prediction model (12). This is 
because they focus purely on the accuracy of the predictions from the model and do not consider 
the clinical consequences of decisions made using the model (13) such as who should receive 
adjuvant therapy. For example, a false positive prediction from the model would result in a patient 
being treated unnecessarily, while a false negative prediction would result in a patient not getting 
a treatment that she would benefit from. The relative harms or benefits of these alternative 
clinical outcomes should be weighted appropriately when evaluating the models. Decision curve 
analysis (14) is a decision-theoretic method to compare prediction models with respect to their 
clinical utility. It provides a calculation of net benefit: the expected utility of a decision to treat 
patients at some threshold, compared to an alternative policy such as treating nobody. “Utility” is 
defined precisely below, however, conceptually, it balances the number of patients whose lives 
are saved against the cost of unnecessarily treating patients who would have survived anyway. In 
practice, adjuvant chemotherapy is recommended as a treatment option from the Cambridge 
Breast Unit (Addenbrooke’s Hospital, Cambridge, UK) if a patient's 10-year predicted survival 
probability using chemotherapy, minus their predicted probability without, is greater than 5% 
(15). Hence, it would be of interest to evaluate whether or not using the existing thresholds 
alongside the current prediction models lead to better clinical utility. 
The aim of this study was three-fold. First, to perform the first direct comparison of 
CancerMath and PREDICT in a large European validation cohort, second, to explore whether 
modelling interactions among the risk factors used in PREDICT and CancerMath can lead to more 
accurate prognostic models, and finally, to exemplify the use of decision curve analysis as a means 
of comparing prognostic models. 
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Methods 
Study population 
Training data 
The training data used for model development was based on data from 5729 patients with 
invasive breast cancer diagnosed in East Anglia, UK between 1999 and 2003 identified by the 
Eastern Cancer Registration and Information Centre (ECRIC). All analyses used data censored on 31 
December 2012. For more details on the source of data and eligibility criteria see (2).  
Information obtained included age at diagnosis (years), ER status (positive or negative), 
tumour grade (I, II, III), tumour size (mm), number of positive lymph nodes, presentation 
(screening vs. clinical), and type of adjuvant therapy (chemotherapy, endocrine therapy, or both). 
Separate models were derived for ER-positive and ER-negative breast cancer. The outcome 
modelled was 10-year breast cancer specific mortality (BCSM). BCSM is defined as time to death 
from breast cancer. 
 
Validation data 
The validation data consisted of three cohorts, the Nottingham/Tenovus Breast Cancer Study 
(1944 subjects) (16), the Breast Cancer Outcome Study of Mutation Carriers (981 subjects) (17), 
and the Prospective Study of Outcomes in Sporadic and Hereditary Breast Cancer (2609 subjects) 
(18). The same predictors as in the training set were available. The outcome measure was again 
10-year BCSM status. If BCSM status was missing, the patient's data were excluded from the 
analysis. CancerMath was validated on a subset of this validation dataset (3431 ER-positive and 
1418 ER-negative subjects) whose tumour size and/or number of positive nodes did not exceed 
the values against which it was originally validated, 50mm and 10 nodes, respectively. 
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Development of novel prognostic models 
We developed novel prognostic models by building upon the existing PREDICT and CancerMath 
frameworks to incorporate interaction terms between the covariates. To this end, we used a 
Bayesian variable selection algorithm, Reversible Jump Markov Chain Monte Carlo (RJMCMC) to 
stochastically search for important interaction terms (19). We present two implementations of the 
algorithm. The first using a Weibull model for the baseline survival time (denoted Weibull 
RJMCMC hereafter), and the second with a logistic regression model for the binary outcome of 10-
year survival (denoted Logistic RJMCMC hereafter). For both models, all predictors were 
transformed as in the latest version of PREDICT (7). The RJMCMC method searched over models 
with all combinations of pairwise interactions between the predictors listed, while including the 
main effects of all predictors in both models.  For further details on the RJMCMC set-up see 
Supplementary Materials.  
Both PREDICT and CancerMath are web-based interfaces, implemented in Javascript. The 
Javascript code, was downloaded in April 2017, and translated into R (20) and subsequently cross-
checked with a random subset of 20 patients, to verify the accuracy of the R translation. Some of 
the predictors used in PREDICT and CancerMath were not available in our data sets, such as the 
chemotherapy generation. We considered that all the patients received second generation 
chemotherapy, as the data were older than 10 years. All other missing predictors were treated as 
unknown. 
 
Comparison of models in terms of predictive performance and decision curve analysis 
We assessed the predictive performance of the models on the validation data by examining 
measures of calibration, discrimination and clinical net benefit. 95% confidence intervals (CI) were 
obtained by bootstrapping using 1000 re-samples of the validation set. 
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Calibration 
Calibration was assessed graphically, by plotting the predicted 10-year mortality risks (x axis) 
against the observed probabilities (y axis), calculated using smoothing techniques (21). Ideally, if 
predicted and observed 10-year survival probabilities agree over the whole range of probabilities, 
the plots show a 45-degree line.  
 
Discrimination 
Discrimination is the ability of the risk score to differentiate between patients who do and do not 
experience the event during the study period. Model discrimination was assessed by calculating 
the area under the receiver-operator characteristic curve (AUC). The AUC is the probability that 
the predicted mortality of a randomly selected patient who died is higher than that of a randomly 
selected patient who survived; the higher the AUC, the better the model is at identifying patients 
with a worse survival. 
 
Decision curve analysis 
We used decision curve analysis to describe and compare the clinical consequences of the models 
(14). The net benefit of a model is the difference between the proportion of true positives (TP) 
and the proportion of false positives (FP) weighted by the threshold R (expressed on the odds 
scale) at which an individual is classified as "high risk": 
𝑁𝑒𝑡 𝑏𝑒𝑛𝑒𝑓𝑖𝑡 =
𝑇𝑃
𝑛
−
𝐹𝑃
𝑛
[
𝑅
1 − 𝑅
]. 
Here n is the total sample size and R is the “high risk designation” threshold at which a treatment 
is prescribed. The risk threshold (R) used by clinicians to prescribe treatment implies a relative 
value for either receiving treatment if death was likely or avoiding treatment if death was not 
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likely. For example, if the clinician views unnecessary chemotherapy in nine women as an 
acceptable cost for correctly treating one high risk woman, this is equivalent to treating all women 
with  10% mortality risk. The decision curve is constructed by varying R and plotting net benefit 
on the y axis against alternative values of R on the x axis. We calculated the net benefit of each 
prediction model and two reference strategies: treat none or treat all. The model with the highest 
net benefit at a particular risk threshold R enables us to treat as many high risk people as possible 
while avoiding harm from unnecessarily treating people at low risk.  
 In practice, treatment for breast cancer is given if it is expected to reduce the predicted 
risk by some desired magnitude, or more. For instance, clinicians in the Cambridge Breast Unit 
(Addenbrooke's Hospital, Cambridge, UK) use the absolute 10-year survival benefit from 
chemotherapy to guide decision making for adjuvant chemotherapy as follows: <3% no 
chemotherapy; 3-5% chemotherapy discussed as a possible option; >5% chemotherapy 
recommended (15). Assuming that chemotherapy reduces the 10-year risk of death by 22% (22), a 
target risk reduction between  3 - 5%, corresponds to risks between 14% and 23% on the decision 
curves. The R software, version 3.3.3 (20) was used for data analysis. 
 
 
Results 
The demographic, pathologic and treatment characteristics for the training and validation sets are 
presented in table 1. Estimated coefficients and the probabilities of inclusion in the model for each 
interaction term are given in the Supplementary Materials (Tables S2-S5 and Figure S1). 
Subsequent performance characteristics are presented only for the validation data. 
 
Calibration 
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Figure 1 shows the calibration plots of the four prognostic models. Individual plots with 95%CIs 
can be found in Supplementary Materials (Figure S2). CancerMath systematically underestimated 
the 10-year death probability, especially for the ER-negative tumours. The other models showed 
good calibration except for high risk individuals, whose risk was consistently overestimated by all 
models. Compared to PREDICT, CancerMath demonstrated worse calibration performance. 
PREDICT outperformed all other models. 
 
Discrimination 
Table 2 represents the percentage change in discriminative performance (PCAUC) of the three 
models with respect to PREDICT. The PCAUC was calculated as follows: PCAUC=(AUCmodel-
AUCPREDICT)/AUCPREDICT100. This allowed us to directly compare the between-model performance. 
The Weibull RJMCMC and Logistic RJMCMC models had superior discrimination to PREDICT for ER-
positive subjects. Logistic RJMCMC also performed better than PREDICT in ER-negative tumours. 
However, none of these improvements were statistically significant. Again, CancerMath 
performed notably worse than PREDICT. 
 
Decision curve analysis 
Figure 2 demonstrates the decision curves for the four models. For risk thresholds  0.05 for ER-
positive tumours and  0.15 for ER-negative tumours, no model provided benefit compared with a 
policy of treating all patients. For threshold probabilities around 0.55 or higher for ER-positive 
tumours and ≥ 0.60 for ER-negative tumours, the models also gave lower net benefit than a policy 
of treating no patients.  Within the threshold range 0.05-0.55 for ER-positive tumours, and 0.15-
0.60 for ER-negative tumours, CancerMath provided the lowest net benefit for both ER-positive 
and ER-negative tumours. All the other curves were very similar over these ranges, indicating that 
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the net-benefit from using any of these models to prescribe chemotherapy, compared to treating 
nobody, could be as high as 0.1, which is of equivalent value to treating an additional 10% of 
patients who would have died without treatment.  
As already mentioned, risks between 14% and 23% correspond to absolute risk reductions from 
chemotherapy treatment, in the range 3-5%. In this range adjuvant chemotherapy is discussed as 
a treatment option (15). Risk >23% correspond to absolute risk reductions of 5% or more where 
chemotherapy is firmly recommended. We see that in both thresholds ranges PREDICT 
outperformed CancerMath. Individual decision curve plots with 95% CIs can be found in 
Supplementary Materials (Figure S3). 
 
Discussion 
Accurate prognostic tools are critical to personalised breast cancer treatment, allowing clinicians 
and patients to make more informed decisions about adjuvant therapy. Using several large 
European validation cohorts, we have performed the first detailed comparison of the two most 
widely used breast cancer prognostic models: PREDICT and CancerMath. We found that survival 
probabilities from PREDICT offer both improved accuracy and discrimination over CancerMath. 
Using decision curve analysis, we also demonstrate that the use of PREDICT to make treatment 
decisions offers greater clinical utility than CancerMath over a range of risk thresholds, including 
those at which adjuvant chemotherapy is currently recommended by clinicians in the UK. We also 
explored novel prognostic models, extending PREDICT to include interaction terms among the 
predictors. Our new models performed as well as PREDICT, but no better, suggesting that, in this 
setting, the incorporation of interaction terms offers no predictive benefit. 
Although all models demonstrated good overall prediction of 10-year mortality for both 
ER-positive and negative tumours, they consistently overestimated risk in women with the worse 
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prognosis. This highlights the shortcoming of current prediction models, showing significant 
discrepancies especially in high-risk populations. Laas et al., (11) arrived at the same conclusion 
but using a smaller sample of ER-positive HER2-negative breast cancer subjects. This could have 
consequences for the individual patient if their survival probability for breast cancer is 
underestimated. 
We further applied decision curve analysis because this offers important information 
beyond the standard performance metrics of discrimination and calibration (14,23). To our 
knowledge, this is the first study to take into account the clinical utility of treatment decisions in 
breast cancer risk models. The main clinical utility of breast cancer prognostic models is to 
facilitate the decision of whether a patient will benefit from systemic treatment or not. Treatment 
is often prescribed at a risk threshold, which implies the clinician or patient's relative value of 
unnecessary treatment vs worthwhile use. From our results, both our models and PREDICT would 
provide the greatest clinical utility when recommending treatment to patients with risks falling in 
the range of 0.05 and 0.55 for ER-positive tumours and between 0.15 and 0.60 for ER-negative 
tumours. It has been suggested that when the absolute 10-year survival benefit from 
chemotherapy is 3-5%, chemotherapy is discussed as a treatment option (15). We demonstrated 
that in this range PREDICT outperformed CancerMath. Note that these calculations assumed a 
22% risk reduction when treated with second generation chemotherapy (22). However, it is 
important to emphasize that there are no studies to date that have evaluated what would be an 
acceptable range of threshold probabilities that would help with adjuvant therapy 
recommendation. 
Several potential limitations of our study should be considered. First, our comparison 
focused on web-based models, which are readily available for use in daily practice and incorporate 
only a modest set of risk factors which would be measured as a matter of course. We also 
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acknowledge that other models may provide more accurate predictions, for example by 
incorporating more biomarker information, such as genetics or other “omics”. Second, some data 
were missing from the validation cohorts, such as the chemotherapy generation, which were 
required in the PREDICT and CancerMath models. As an approximation, we assumed that all 
patients received second generation chemotherapy since the data were older than 10 years. Since 
this same approximation was used in the fitting and validation of all models, we think it is unlikely 
to add much bias to their relative performance. We also note that any patient with missing 
information (predictors or outcome) was excluded from the training and validation data. Overall 
this was a small number of patients (<5%) so is unlikely to have biased our results. 
In summary, we have compared two widely used prediction models for survival in patients 
with early stage breast cancer, PREDICT and CancerMath. The former outperformed the latter in 
discriminatory accuracy, calibration and clinical utility. We also developed novel prognostic 
models which performed as well as PREDICT, indicating that the incorporation of interaction terms 
offers only marginal predictive benefit. We have shown that PREDICT offers robust predictive 
performance, equivalent to our more complex modelling strategy, and for the first time quantified 
its clinical utility in identifying high risk women that would benefit from adjuvant treatment. We 
did not elicit the relative benefits and harms of treatment directly from patients or clinicians, but 
inferred them from the risk threshold currently used to prescribe chemotherapy. Further research 
will be required to more precisely determine relative utilities of treatment vs no treatment, which 
could lead to new risk thresholds to focus decision curve analysis on. 
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Figures 
 
 (A) ER positive 
 
 (B) ER negative 
Figure 1: Calibration plots of the four models in the validation set for (A) ER positive, and (B) 
ER negative tumours. Ten-year mortality risks based on the four prognostic models are plotted 
against the observed mortality rate. The 45-degree line represents the perfect calibration slope. 
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 (A) ER positive 
 
 
 (B) ER negative 
Figure 2: Decision curve analysis for 10-year mortality for each model for (A) ER positive, and (B) 
ER negative tumours. The y axis measures net benefit. The 0.14 to 0.23 shaded area on the x axis 
corresponds to 3-5% absolute risk of death reduction with and without chemotherapy assuming a 
relative risk reduction of 22% if treated. These are the risk ranges where chemotherapy is 
discussed as a treatment option. A model is of clinical value if it has the highest net benefit 
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compared with the simple strategies of treating all patients (black line) or no patients (horizontal 
gray line) across the full range of threshold probabilities at which a patient would choose to be 
treated. The units on the y axis may be interpreted as the benefit associated with one patient who 
would die without treatment and who receives therapy. 
 
 
Tables  
Table 1: Characteristics of women in the training and validation data sets. 
 Training data Validation data 
Total number of women 5729 5534 
Breast cancer deaths, n (%) 994 (17) 1079 (20) 
Missing breast cancer deaths, 
n (%) 
0 (0) 118 (2) 
Other deaths, n (%) 680 (12) 208 (4) 
Missing other deaths, n (%) 0 (0) 118 (2) 
Median age at diagnosis (IQR), 
years  
58 (17) 40 (13) 
Median tumor size (IQR), mm 19 (13) 20 (15) 
Missing tumor size, n (%)  0 (0) 157 (3) 
Median number of nodes 
(IQR) 
0 (2) 0 (2) 
Grade, n (%)   
I 987 (18) 702 (13) 
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II 2932 (51) 1918 (35) 
III  1810 (32) 2914 (53) 
ER status, n (%)   
Positive  4711 (82) 3879 (70) 
Negative  1018 (18) 1655 (30) 
Adjuvant therapy, n (%)    
None  735 (13) 1310 (24) 
Chemo  909 (16) 1562 (28) 
Hormone  2981 (52) 1020 (18) 
Both 1104 (19) 1642 (30) 
 
 
 
Table 2: Percentage change in AUC (PCAUC) between PREDICT and each of the other models. The 
95% confidence intervals (CI) are based on 1000 bootstrap replicates 
 
 
 
 
 ER positive ER negative 
PREDICT vs  PCAUC (%) 95% CI PCAUC (%) 95% CI 
CancerMath  -4.27 -6.39 – -2.03 -3.21 -5.9 – -0.48 
Logistic RJMCMC  0.04 -1.04 – 1.12 0.19 -0.19 – 0.57 
Weibull RJMCMC  0.06 -0.96 – 1.11 -0.4 -0.83 – 0.03 
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